ライフサイエンスコーパス: alteplase

1 Intravenous tPA (recombinant alteplase).

2 5 allocated tenecteplase and n=892 allocated alteplase).

3 associated with increased and timely use of alteplase.

4 675 (14%) of the enrollees were treated with alteplase.

5 rombectomy for ischemic stroke compared with alteplase.

6 s to be tested as a potential alternative to alteplase.

7 n to the substantial efficacy of intravenous alteplase.

8 ecting good stroke outcome in patients given alteplase.

9 r thrombolytic therapy with streptokinase or alteplase.

10 Intravenous thrombolysis with alteplase.

11 resolve with thrombolytic treatment, such as alteplase.

12 us alteplase and six received intra-arterial alteplase.

13 se and 4.5 h (3.8-24.0 h) for intra-arterial alteplase.

14 do not improve on treatment with intravenous alteplase.

15 pectively, compared with 0%, 0%, and 23% for alteplase.

16 apleural instillation of either urokinase or alteplase.

17 y 70% in the two groups received intravenous alteplase.

18 ow when combined with half the usual dose of alteplase.

19 of coronary thrombolysis with reteplase and alteplase.

20 th the thrombolytic agents streptokinase and alteplase.

21 = 0.003) and thrombin (p = 0.009) than after alteplase.

22 higher at 24 h after thrombolysis than after alteplase.

23 tion, with heparin, aspirin, and accelerated alteplase.

24 se among the 2175 actually given intravenous alteplase.

25 and partially mitigated by intraventricular alteplase.

26 on of treatment effect in patients receiving alteplase.

27 1.13-5.94; P=0.032) than those treated with alteplase.

28 treptokinase and non-accelerated infusion of alteplase.

29 e tenecteplase 0.25 mg/kg (maximum 25 mg) or alteplase 0.9 mg/kg (maximum 90 mg).

30 andard medical care or image-guided MIS plus alteplase (0.3 mg or 1.0 mg every 8 h for up to nine dos

31 we randomly assigned 75 patients to receive alteplase (0.9 mg per kilogram of body weight) or tenect

32 Stroke Scale score change: tenecteplase, 6; alteplase, 1; P<0.001) and better late independent recov

33 ssigned to treatment with placebo (n = 151), alteplase 10 mg (n = 144), or alteplase 20 mg (n = 145)

34 ssigned to treatment with placebo (n = 151), alteplase 10 mg (n = 144), or alteplase 20 mg (n = 145).

35 s the placebo group; if not significant, the alteplase 10-mg group vs the placebo group was considere

36 e enrolled, of whom 238 received intravenous alteplase (120 in the intervention group and 118 in the

37 The most promising regimen was 50 mg of alteplase (15-mg bolus; infusion of 35 mg over 60 minute

38 rate of stroke in women after treatment with alteplase (2.0% vs 1.9% with streptokinase and intraveno

39 .97), and those not eligible for intravenous alteplase (2.43, 1.30-4.55).

40 Stroke Scale score change: tenecteplase, 7; alteplase, 2; P=0.018) and less parenchymal hematoma (2

41 ebo (n = 151), alteplase 10 mg (n = 144), or alteplase 20 mg (n = 145) by manual infusion over 5 to 1

42 ebo (n = 151), alteplase 10 mg (n = 144), or alteplase 20 mg (n = 145).

43 The primary comparison was the alteplase 20-mg group vs the placebo group; if not signi

44 lone or in combination with reduced doses of alteplase (20 to 65 mg) or streptokinase (500 000 U to 1

45 ibrinolytic assignment (streptokinase, 4.1%; alteplase, 4.3%; reteplase, 4.5%; combined streptokinase

46 reteplase, 4.5%; combined streptokinase and alteplase, 4.4%; P=0.55).

47 dian NIHSS 7 (range 1-30), 38 (46%) received alteplase, 41 (49%) had died or were dependent at 3 mont

48 We investigated the safety and efficacy of alteplase, a recombinant tissue plasminogen activator, i

49 regimens as reperfusion therapy in STEMI and alteplase (accelerated infusion), tenecteplase, and rete

50 pitals achieving shorter door to intravenous alteplase administration (door to needle) times were mor

51 st to callback, and time from teleconsult to alteplase administration all decreased (all P<0.01).

52 triaging, off-hour presentation, intravenous alteplase administration, use of general anesthesia, and

53 -independent device to patients treated with alteplase after acute ischaemic stroke was feasible and

54 functional outcome in patients treated with alteplase after acute ischaemic stroke.

55 The ability to cryopreserve alteplase aliquots makes it an economically reasonable a

56 jor hemorrhage were 6% in patients receiving alteplase alone (n=235), 3% with abciximab alone (n=32),

57 o patients who were treated with intravenous alteplase alone from the International Stroke Perfusion

58 inutes for patients treated with accelerated alteplase alone was 57% compared with 32% for abciximab

59 litaire FR stent retriever, as compared with alteplase alone, improved reperfusion, early neurologic

60 clinical outcomes compared with intravenous alteplase alone.

61 on) stent retriever or to continue receiving alteplase alone.

62 tients and 132 matched controls treated with alteplase alone.

63 However, alteplase also increases the risk of intracerebral haemo

64 Primary treatment success was 98% for alteplase and 100% for urokinase, with no major complica

65 en in 96 (5.2%) of 1850 patients assigned to alteplase and 18 (1.0%) of 1820 controls, with no clear

66 was 3.3 h (range 2.0-52.0 h) for intravenous alteplase and 4.5 h (3.8-24.0 h) for intra-arterial alte

67 ividuals, of whom 429 (51%) were assigned to alteplase and 414 (49%) to placebo or standard care.

68 Of 146 pooled patients, 71 received alteplase and 75 received tenecteplase.

69 he majority of patients received intravenous alteplase and concomitant full-dose heparin.

70 vailable 2 treatment options are intravenous alteplase and endovascular therapy (mechanical clot remo

71 REACH is presently being used to give alteplase and guide acute stroke care in eight rural com

72 e occurred in 199 (47%) of 420 patients with alteplase and in 160 (39%) of 409 patients among control

73 obstruction did not differ between the 20-mg alteplase and placebo groups (3.5% vs 2.3%; estimated di

74 tudies showed rapid clearance of circulating alteplase and recovery of plasminogen activator inhibito

75 eceived alteplase: nine received intravenous alteplase and six received intra-arterial alteplase.

76 Multiple variables were compared for the alteplase and urokinase groups by using univariate and m

77 t in the use of thrombolytic treatment (with alteplase) and lipid testing.

78 target occlusion, infarct core, pretreatment alteplase), and the collateral score.

79 eived intravenous thrombolysis (70% received alteplase, and 30% received tenecteplase), and 225 patie

80 features, adherence to adult guidelines for alteplase, and outcomes.

81 erapy in STEMI (streptokinase, tenecteplase, alteplase, and reteplase) were included.

82 ssociated illnesses, after thrombolysis with alteplase, and when therapies were initiated outside app

83 uate the dose and the safety and efficacy of alteplase are needed in childhood stroke.

84 Cryopreserved 1-mg/mL aliquots of alteplase are safe and effective in the clearance of occ

85 However, the practicality of using alteplase as the thrombolytic of choice for this indicat

86 All patients received accelerated alteplase, aspirin, and intravenous heparin infusion; al

87 as Integrilin, is combined with accelerated alteplase, aspirin, and intravenous heparin.

88 incoming stroke patients; (2) administering alteplase at the computed tomography (CT) scanner; and (

89 longer among patients receiving intravenous alteplase at the referring hospital (drip and ship) vers

90 ed plasma clots with either streptokinase or alteplase, at therapeutic levels, increased the availabl

91 han waiting for an assessment of response to alteplase, because minimising time to reperfusion is the

92 tients (89.0%) were treated with intravenous alteplase before randomization.

93 ed efficacy and safety profile compared with alteplase, benefits possibly exaggerated in patients wit

94 tember 2, 1995, and March 27, 1998, and with alteplase between March 30, 1998, and January 2, 2002.

95 A focus on extending the time window for alteplase beyond 4.5 hours has encumbered substantial re

96 >=10) who received intravenous thrombolysis (alteplase bolus) within 3 h of symptom onset in North Am

97 ich had to be activated within 30 min of the alteplase bolus.

98 in addition to thrombolysis with intravenous alteplase, but benefits were also reported in patients i

99 clots using surgical aspiration followed by alteplase clot irrigation.

100 ombectomy, the use of adjunct intra-arterial alteplase compared with placebo resulted in a greater li

101 ts (35 assigned tenecteplase and 36 assigned alteplase) contributing to the primary endpoint, no sign

102 itially to either 100 mg of accelerated-dose alteplase (control) or abciximab (bolus 0.25 mg/kg and 1

103 [AUC], 0.89; 95% CI, 0.84, 0.94), whereas in alteplase controls the optimal ischemic core threshold r

104 Alteplase delivered into the ICH in MISTIE-III subjects

105 tine extraventricular drain, irrigation with alteplase did not substantially improve functional outco

106 Overall, there was no association between alteplase dose and the extent of MVO (p for trend = 0.12

107 The interaction between ischemic time and alteplase dose was statistically significant (p = 0.018)

108 No imaging features modified the effect of alteplase dose.

109 imaging features showed no interaction with alteplase dose.

110 (A Trial of Low-Dose Adjunctive Alteplase During Primary PCI [T-TIME]; NCT02257294).

111 e T-TIME trial (Trial of Low-Dose Adjunctive Alteplase During Primary PCI), 440 patients with acute S

112 nctive treatment with low-dose intracoronary alteplase during primary percutaneous coronary intervent

113 alfimeprase doses were more successful than alteplase during the first 15 and 30 minutes of treatmen

114 In all study patients, the use of alteplase either did not achieve revascularization or wa

115 or mistaken or duplicate randomisation, 2196 alteplase-eligible patients with acute ischaemic stroke

116 nts to image-guided MISTIE treatment (1.0 mg alteplase every 8 h for up to nine doses) or standard me

117 Intrapleural fibrinolysis with urokinase or alteplase facilitates thoracostomy tube drainage of para

118 current practices and results of the use of alteplase for acute arterial ischaemic stroke in childre

119 short-term outcome in children treated with alteplase for acute arterial ischaemic stroke who were e

120 d pressure lowering in patients treated with alteplase for acute ischaemic stroke.

121 ommon data elements from six other trials of alteplase for acute stroke (2775 patients).

122 e reports and with guidelines for the use of alteplase for adult stroke.

123 ogram) was superior to the lower dose and to alteplase for all efficacy outcomes, including absence o

124 rial and the Minimally Invasive Surgery Plus Alteplase for Intracerebral Hemorrhage Evacuation Phase

125 s treatment being applied in those receiving alteplase for mild-to-moderate acute ischaemic stroke.

126 linical trials of tenecteplase compared with alteplase for the treatment of acute ischemic stroke, 1

127 ted randomised phase 3 trials of intravenous alteplase for treatment of acute ischaemic stroke for wh

128 eptokinase and Tissue plasminogen activator (alteplase) for Occluded coronary arteries (GUSTO I) and

129 in the Global Use of Streptokinase and TPA (alteplase) for Occluded Coronary arteries (GUSTO)-I tria

130 Thrombolysis with streptokinase or alteplase further increased both parameters, which peake

131 symptoms, adjunctive low-dose intracoronary alteplase given during the primary percutaneous interven

132 In most countries, alteplase given within 4.5 h of onset is the only approv

133 e was similar in each group (good outcome in alteplase group 48% vs saline 45%; risk ratio [RR] 1.06

134 27 (6%) patients died in the alteplase group and 14 (3%) patients died among controls

135 analysis from 246 of 249 participants in the alteplase group and 245 of 251 participants in the place

136 15, 500 patients were randomised: 249 to the alteplase group and 251 to the saline group.

137 ompleted follow-up: 54 (56%) in the MIS plus alteplase group and 42 (44%) in the standard medical car

138 52 were assigned to the alteplase group and 52 to tenecteplase.

139 group compared with 75 (8%) patients in the alteplase group died, symptomatic intracerebral haemorrh

140 c intracranial haemorrhage was higher in the alteplase group than among controls (11 [3%] vs two [<1%

141 aemorrhages were more common in the MIS plus alteplase group than in the standard medical care group

142 mortality at 90 days was 608 (17.9%) in the alteplase group versus 556 (16.5%) in the control group

143 Symptomatic bleeding (six [2%] in the alteplase group vs five [2%] in the saline group; RR 1.2

144 In the alteplase group, 90 (21%) patients were severely disable

145 n the placebo group, 18 (12.9%) in the 10-mg alteplase group, and 12 (8.2%) in the 20-mg alteplase gr

146 initely related to drug treatment; 16 in the alteplase group, five were considered drug-related).

147 l improvement (P<0.001) at 24 hours than the alteplase group.

148 (0.92-1.61) for 271-360 min in favour of the alteplase group.

149 alteplase group, and 12 (8.2%) in the 20-mg alteplase group.

150 r the tenecteplase group vs 68% [23] for the alteplase group; mean difference 1.3% [95% CI -9.6 to 12

151 did not differ between the tenecteplase and alteplase groups.

152 tween the standard medical care and MIS plus alteplase groups: 30 day mortality (four [9.5%, 95% CI 2

153 Participants allocated to alteplase had a significantly higher hazard of death dur

154 Alteplase has been reported as an efficacious alternativ

155 IV nerinetide (2.6 mg/kg of body weight) and alteplase (if indicated) treatment vs best medical manag

156 mbinant tissue plasminogen activator (rt-PA, alteplase) improved functional outcome in patients treat

157 Use of alteplase improves outcome in some patients with stroke.

158 Randomised trials have shown that alteplase improves the odds of a good outcome when deliv

159 lar thrombectomy with or without intravenous alteplase in acute stroke.

160 own, STAT stroke protocol, and administering alteplase in CT are associated with lower DTN time.

161 ferences were found between tenecteplase and alteplase in effectiveness or safety outcomes for the ov

162 erapy with tenecteplase would be superior to alteplase in improving functional outcomes in the group

163 The treatment benefit of alteplase in patients with a DWI-FLAIR mismatch seems to

164 n to thrombolytic treatment with intravenous alteplase in patients with acute ischaemic stroke, but t

165 etter reperfusion and clinical outcomes than alteplase in patients with stroke who were selected on t

166 following factors to be significant: giving alteplase in the CT (32% decrease in DTN time, 95% confi

167 The increase in use of alteplase in the target population was significant, but

168 rwent endovascular thrombectomy and received alteplase in usual care when indicated.

169 th stroke who were admitted and treated with alteplase increased between the pre-intervention and pos

170 he percent of eligible patients treated with alteplase increased by 8% (P=0.03).

171 n patients with an ischemic time >=4 to 6 h, alteplase increased the mean extent of MVO compared with

172 Alteplase increased the odds of a good stroke outcome, w

173 Alteplase increased the odds of type 2 parenchymal haemo

174 Children with acute stroke received alteplase infrequently and at time intervals that often

175 ic strategy involving low-dose intracoronary alteplase infused early after coronary reperfusion assoc

176 a fibrin-binding thrombolytic agent such as alteplase is an alternative to continuous-infusion throm

177 Alteplase is currently the only approved thrombolytic ag

178 Alteplase is effective for treatment of acute ischaemic

179 However, the recanalisation rate with alteplase is modest.

180 We aimed to establish whether intravenous alteplase is safe and effective in such patients when sa

181 ery occlusion on a background of intravenous alteplase is safe, improves excellent clinical outcomes

182 Intravenous alteplase is the only approved treatment for acute ische

183 th and disability worldwide, and intravenous alteplase is the only proven effective treatment in the

184 Although intravenous alteplase (IV-tPA) has a beneficial effect on functional

185 the administration of additional intravenous alteplase (IVT) before mechanical thrombectomy (MT).

186 direct intraclot lacing of the thrombus with alteplase (maximum daily dose, 50 mg per leg per day; ma

187 Intracoronary alteplase may be harmful for this subgroup.

188 ts were matched to 797 patients treated with alteplase (median age = 70 years, 43.9% women, median Na

189 onset in 3670 patients randomly allocated to alteplase (n=1850) or to placebo (n=1820).

190 andomly assigned to tenecteplase (n=339) and alteplase (n=341), all of whom were included in the inte

191 randomly assigned to tenecteplase (n=716) or alteplase (n=714).

192 troke enrolled in the IPSS, 15 (2%) received alteplase: nine received intravenous alteplase and six r

193 t hoc analysis of patients who also received alteplase, NXY-059 was associated with a lower incidence

194 Intracranial haemorrhage after alteplase occurred in four of 15 patients, although none

195 This improvement in reperfusion with alteplase occurred without an increase in the risk of ma

196 We report the effect of intravenous alteplase on long-term survival after ischaemic stroke o

197 The effect of alteplase on patient survival after ischaemic stroke is

198 The effects of reteplase and alteplase on platelet aggregation and major surface anti

199 have expressed concerns about the effect of alteplase on survival.

200 ine the proportional and absolute effects of alteplase on the risks of intracerebral haemorrhage, mor

201 of time to treatment with intravenous rt-PA (alteplase) on therapeutic benefit and clinical risk by a

202 n the endovascular-therapy group than in the alteplase-only group (median, 100% vs. 37%; P<0.001).

203 mg alteplase plus abciximab group versus the alteplase-only group at both 60 minutes (72% versus 43%;

204 receive up to 12 doses, 8 h apart of 1 mg of alteplase or 0.9% saline via the extraventricular drain.

205 AMI before and after reperfusion with either alteplase or reteplase or reduced doses of these agents

206 When combined with reduced doses of either alteplase or reteplase, abciximab achieved 91% and 83% i

207 enhance patient selection are investigating alteplase, other thrombolytic drugs, and novel endovascu

208 te models showed greater total drainage with alteplase (P <.001), greater patient age (P <.001), larg

209 inition, 1/52 [2%] tenecteplase vs 2/51 [4%] alteplase, p=0.55; by ECASS II definition, 3/52 [6%] vs

210 at 90 days (in 72% of patients, vs. 40% with alteplase; P=0.02).

211 ischemic stroke who were receiving 0.9 mg of alteplase per kilogram of body weight less than 4.5 hour

212 ase plus abciximab (n=143), 7% with 50 mg of alteplase plus abciximab and low-dose heparin (n=103), a

213 rates were significantly higher in the 50-mg alteplase plus abciximab group versus the alteplase-only

214 w-dose heparin (n=103), and 1% with 50 mg of alteplase plus abciximab with very-low-dose heparin (n=7

215 .82-times compared with accelerated infusion alteplase plus parenteral anticoagulants (RR 1.47 [95% C

216 nts; RR 1.26 [1.10-1.45] for non-accelerated alteplase plus parenteral anticoagulants).

217 sation, 453 (47%) of 967 participants in the alteplase plus standard care group and 494 (50%) of 979

218 e included in the analysis (967 [50%] in the alteplase plus standard care group and 979 [50%] in the

219 he first 7 days (99 [10%] of 967 died in the alteplase plus standard care group vs 65 [7%] of 979 in

220 atio to treatment with intravenous 0.9 mg/kg alteplase plus standard care or standard care alone with

221 65%) of 207 patients assigned to intravenous alteplase plus thrombectomy (adjusted risk difference -7

222 ete intraventricular haemorrhage removal via alteplase produces gains in functional status.

223 With the dosing regimen used in this study, alteplase produces greater thoracostomy tube output than

224 ith increasing duration of administration of alteplase, progressing from a bolus alone to a bolus fol

225 ly, we observed changes in the indication of alteplase (pulmonary embolism indication increased in ho

226 vascular treatment compared with intravenous alteplase (recombinant tissue plasminogen activator) alo

227 the exposure of an intracranial thrombus to alteplase (recombinant tissue plasminogen activator), po

228 symptom onset, and 24,705 patients received alteplase (recombinant tissue-type plasminogen activator

229 Although no alteplase-related deaths or symptomatic intracranial hae

230 e basis of available trial data, intravenous alteplase remains the initial treatment for all eligible

231 DWI-FLAIR or perfusion mismatch, intravenous alteplase resulted in better functional outcome at 90 da

232 MIS plus alteplase seems to be safe in patients with intracerebra

233 e during the first few days after treatment, alteplase significantly improves the overall odds of a g

234 Alteplase significantly increased the odds of symptomati

235 s received a sufficient volume of the thawed alteplase solution to fill the occluded catheter(s).

236 erine protease tissue plasminogen activator (alteplase, t-PA), and have prolonged half-life features

237 was recorded between accelerated infusion of alteplase, tenecteplase, and reteplase with parenteral a

238 In the Alteplase-Tenecteplase Trial Evaluation for Stroke Throm

239 Although there were more deaths with alteplase than placebo, there were fewer cases of severe

240 Greater pleural fluid drainage occurred with alteplase than urokinase during the 1st (P =.001) and 2n

241 Among patients given alteplase, the net outcome is predicted both by time to

242 ublished articles who were given intravenous alteplase, the nine patients in the IPSS cohort were mos

243 platelet characteristics after reteplase and alteplase therapy in the setting of the Global Use of St

244 interval, 0.89-3.51; P=0.102) compared with alteplase therapy.

245 The Alteplase ThromboLysis for Acute Noninterventional Thera

246 intravenous heparin; (3) streptokinase plus alteplase (tissue-type plasminogen activator) with intra

247 These systems are being used to give alteplase to patients with stroke in previously underser

248 nt to plasminogen activator inhibitor-1 than alteplase TPA.

249 ts received a weight-adjusted dose of either alteplase (tPA) (2 to 5 mg/h) or tenecteplase (TNK) (0.5

250 versus 24.3ml (IQR, 16.7-42.2; p = 0.011) in alteplase-treated controls.

251 The numbers of consults and alteplase-treated patients increased annually, even afte

252 score of 0 to 1 versus 2 to 6 compared with alteplase-treated patients using linear regression to ge

253 Data from 350 consecutive alteplase-treated patients were analyzed.

254 Patients were stratified by intravenous alteplase treatment and declared endovascular device cho

255 ility of achieving an excellent outcome with alteplase treatment exceeds the risk of death, early tre

256 r of telestroke consults per year) and spoke alteplase treatment metrics in an academic telestroke ne

257 s OTT decreased (p=0.0269) and no benefit of alteplase treatment was seen after around 270 min.

258 Alteplase treatment within 6 h after ischaemic stroke wa

259 o not regain functional independence despite alteplase treatment.

260 ere also reported in patients ineligible for alteplase treatment.

261 23 patients with stroke received intravenous alteplase treatment.

262 1 levels within 2 hours after termination of alteplase treatment.

263 ts with target mismatch (33 tenecteplase, 35 alteplase), treatment with tenecteplase was associated w

264 f intracerebral haemorrhage on allocation to alteplase, treatment delay, age, and stroke severity.

265 e and quantitative assessment of barriers to alteplase use and ways to address the findings, and prov

266 , multicomponent intervention could increase alteplase use in community hospitals in Michigan, USA.

267 target-population analysis, the increase in alteplase use in intervention hospitals (59 [1.00%] of 5

268 intervention did not significantly increase alteplase use in patients with ischaemic stroke.

269 The primary outcome was change in alteplase use in patients with stroke in emergency depar

270 le score, ASPECTS, occlusion location, site, alteplase use, and declared first device.

271 ute ischemic stroke treated with intravenous alteplase, use of NOACs within the preceding 7 days, com

272 for 259 (32.9%) of 787 patients who received alteplase versus 176 (23.1%) of 762 who received control

273 rticipants in the nine trials of intravenous alteplase versus control.

274 (STT) meta-analysis of randomised trials of alteplase versus placebo (or untreated control) in patie

275 to remove intraventricular haemorrhage with alteplase versus saline irrigation improved functional o

276 Randomised trials of intravenous alteplase versus standard of care or placebo in adults w

277 ing in 231 [6.8%] of 3391 patients allocated alteplase vs 44 [1.3%] of 3365 patients allocated contro

278 2.41%; P = .32) nor in the analysis of 10-mg alteplase vs placebo groups (2.6% vs 2.3%; estimated dif

279 es (P=0.02), number of patients treated with alteplase was an additional 1.7 (P<0.01), and the percen

280 Alteplase was associated with a significant shift toward

281 but the absolute excess risk attributable to alteplase was bigger among patients who had more severe

282 Alteplase was chosen because its high fibrin affinity ob

283 To make this approach economically feasible, alteplase was diluted to 1 mg/mL and 2.5-mL aliquots wer

284 Among thrombolytic drugs, alteplase was most strongly associated with favorable ou

285 mbus burden, intracoronary administration of alteplase was not superior to placebo in reducing the co

286 rease in fatal intracranial haemorrhage from alteplase was similar irrespective of treatment delay, a

287 us recombinant tissue plasminogen activator (alteplase) was approved by the US Food and Drug Administ

288 treptokinase and non-accelerated infusion of alteplase were significantly associated with an increase

289 ither medical therapy (including intravenous alteplase when eligible) and endovascular therapy with t

290 ed to medical therapy (including intravenous alteplase when eligible) and neurovascular thrombectomy

291 cal symptoms and CT benefit from intravenous alteplase when treated up to 4.5 h.

292 oven efficacy for acute ischaemic stroke was alteplase, which is approved for use within 4.5 h after

293 Protocol-based use of alteplase with extraventricular drain seems safe.

294 with intravenous heparin; or (4) accelerated alteplase with intravenous heparin.

295 Compared with accelerated infusion of alteplase with parenteral anticoagulants as background t

296 patients in nine randomised trials comparing alteplase with placebo or open control.

297 sure lowering with dose (low vs standard) of alteplase with regard to the primary outcome.

298 e efficacy and safety of tenecteplase versus alteplase within 4.5 h of stroke onset in a population n

299 rsus placebo in stroke patients treated with alteplase within 4.5 hours of onset.

300 ment of middle cerebral artery), intravenous alteplase (yes vs no), baseline Alberta Stroke Program E